MX378963B - Compuestos de naftiridina como inhibidores de quinasa jak. - Google Patents
Compuestos de naftiridina como inhibidores de quinasa jak.Info
- Publication number
- MX378963B MX378963B MX2017015211A MX2017015211A MX378963B MX 378963 B MX378963 B MX 378963B MX 2017015211 A MX2017015211 A MX 2017015211A MX 2017015211 A MX2017015211 A MX 2017015211A MX 378963 B MX378963 B MX 378963B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- kinase inhibitors
- jak kinase
- naphthyridine compounds
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona compuestos de la fórmula (I): (ver Fórmula) en donde las variables se definen en la especificación, o una sal farmacéuticamente aceptable del mismo, que son inhibidores de quinasas JAK. La invención también proporciona composiciones farmacéuticas que comprenden tales compuestos, métodos para usar tales compuestos para tratar enfermedades intestinales inflamatorias, y procesos e intermediarios útiles para preparar tales compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167694P | 2015-05-28 | 2015-05-28 | |
| US201662312273P | 2016-03-23 | 2016-03-23 | |
| PCT/US2016/034243 WO2016191524A1 (en) | 2015-05-28 | 2016-05-26 | Naphthyridine compounds as jak kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017015211A MX2017015211A (es) | 2018-04-13 |
| MX378963B true MX378963B (es) | 2025-03-10 |
Family
ID=56118022
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011774A MX2020011774A (es) | 2015-05-28 | 2016-05-26 | Compuestos de naftiridina como inhibidores de quinasa jak. |
| MX2017015211A MX378963B (es) | 2015-05-28 | 2016-05-26 | Compuestos de naftiridina como inhibidores de quinasa jak. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011774A MX2020011774A (es) | 2015-05-28 | 2016-05-26 | Compuestos de naftiridina como inhibidores de quinasa jak. |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9725470B2 (es) |
| EP (2) | EP3303348B1 (es) |
| JP (4) | JP6692836B2 (es) |
| KR (1) | KR20180011272A (es) |
| CN (2) | CN107667108B (es) |
| AU (2) | AU2016267141B2 (es) |
| BR (1) | BR112017025542A2 (es) |
| CA (1) | CA2983453A1 (es) |
| CL (1) | CL2017002994A1 (es) |
| CO (1) | CO2017012267A2 (es) |
| CY (1) | CY1122279T1 (es) |
| DK (1) | DK3303348T3 (es) |
| EA (1) | EA032953B1 (es) |
| ES (2) | ES2924698T3 (es) |
| HK (1) | HK1245771A1 (es) |
| HU (1) | HUE046130T2 (es) |
| IL (3) | IL255358B (es) |
| LT (1) | LT3303348T (es) |
| ME (1) | ME03610B (es) |
| MX (2) | MX2020011774A (es) |
| PH (1) | PH12017502050A1 (es) |
| PL (1) | PL3303348T3 (es) |
| PT (1) | PT3303348T (es) |
| RS (1) | RS59522B1 (es) |
| SA (1) | SA517390337B1 (es) |
| SG (1) | SG10201910742VA (es) |
| SI (1) | SI3303348T1 (es) |
| SM (1) | SMT201900587T1 (es) |
| TW (2) | TWI746178B (es) |
| UA (1) | UA121138C2 (es) |
| WO (1) | WO2016191524A1 (es) |
| ZA (1) | ZA201707326B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3303348B1 (en) | 2015-05-28 | 2019-08-07 | Theravance Biopharma R&D IP, LLC | Naphthyridine compounds as jak kinase inhibitors |
| EP3831830A1 (en) | 2015-11-03 | 2021-06-09 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| PL3712152T3 (pl) | 2015-11-03 | 2021-08-02 | Topivert Pharma Limited | Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych |
| AU2017258186B2 (en) | 2016-04-28 | 2020-09-17 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as JAK kinase inhibitors |
| HRP20220885T1 (hr) | 2016-12-16 | 2022-12-09 | Janssen Pharmaceutica Nv | Spojevi imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaze |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| GEP20227344B (en) | 2017-10-27 | 2022-01-25 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| TWI740288B (zh) * | 2018-11-27 | 2021-09-21 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| CN115925705B (zh) | 2018-11-30 | 2024-12-31 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| AR118767A1 (es) | 2019-04-24 | 2021-10-27 | Theravance Biopharma R&D Ip Llc | Pirimidinas sustituidas como inhibidores de jak y su uso para el tratamiento de enfermedades inflamatorias o autoinmunes cutáneas |
| HUE066802T2 (hu) | 2019-04-24 | 2024-09-28 | Theravance Biopharma R&D Ip Llc | JAK kináz inhibitor észter és karbonát pirimidin vegyületek |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021238908A1 (zh) * | 2020-05-25 | 2021-12-02 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的盐、晶型及其制备方法 |
| CN113717202A (zh) * | 2020-05-25 | 2021-11-30 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的自由碱晶型及其制备方法 |
| WO2022076717A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solvate forms of a pan-jak inhibitor |
| CN116368134A (zh) | 2020-10-09 | 2023-06-30 | 施万生物制药研发Ip有限责任公司 | 制备泛jak抑制剂的方法和相关中间体化合物 |
| WO2022076714A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solid forms of a pan-jak inhibitor |
| TW202228689A (zh) * | 2020-10-09 | 2022-08-01 | 美商賽若凡斯生物製藥研發智財有限責任公司 | 泛ｊａｋ抑制劑的調配物 |
| US20240158392A1 (en) * | 2021-02-01 | 2024-05-16 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| WO2022241188A1 (en) | 2021-05-14 | 2022-11-17 | Theravance Biopharma R&D Ip, Llc | Enantioselective synthesis of aminotropane compound |
| WO2023011359A1 (zh) * | 2021-08-05 | 2023-02-09 | 南京明德新药研发有限公司 | 桥环类化合物及其应用 |
| WO2023102800A1 (en) | 2021-12-09 | 2023-06-15 | Theravance Biopharma R&D Ip, Llc | Synthesis of 5, 7-dichloro-1, 6-naphthyridine |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
| WO2024022444A1 (zh) | 2022-07-27 | 2024-02-01 | 江苏恒瑞医药股份有限公司 | 稠环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6653301B2 (en) | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1595881A1 (en) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| CA2682646A1 (en) * | 2007-04-02 | 2008-10-09 | Palau Pharma, S.A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| WO2010002472A1 (en) * | 2008-07-02 | 2010-01-07 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| JP2011529932A (ja) * | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| JP2012504157A (ja) | 2008-09-30 | 2012-02-16 | アストラゼネカ アクチボラグ | 複素環式ｊａｋキナーゼ阻害剤 |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| CN105367555B (zh) | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| EP3303348B1 (en) | 2015-05-28 | 2019-08-07 | Theravance Biopharma R&D IP, LLC | Naphthyridine compounds as jak kinase inhibitors |
| AU2017258186B2 (en) | 2016-04-28 | 2020-09-17 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as JAK kinase inhibitors |
-
2016
- 2016-05-26 EP EP16728495.9A patent/EP3303348B1/en active Active
- 2016-05-26 UA UAA201712873A patent/UA121138C2/uk unknown
- 2016-05-26 BR BR112017025542-1A patent/BR112017025542A2/pt active Search and Examination
- 2016-05-26 RS RS20191390A patent/RS59522B1/sr unknown
- 2016-05-26 DK DK16728495T patent/DK3303348T3/da active
- 2016-05-26 PL PL16728495T patent/PL3303348T3/pl unknown
- 2016-05-26 KR KR1020177037794A patent/KR20180011272A/ko not_active Ceased
- 2016-05-26 HU HUE16728495A patent/HUE046130T2/hu unknown
- 2016-05-26 SI SI201630490T patent/SI3303348T1/sl unknown
- 2016-05-26 AU AU2016267141A patent/AU2016267141B2/en not_active Ceased
- 2016-05-26 MX MX2020011774A patent/MX2020011774A/es unknown
- 2016-05-26 SG SG10201910742VA patent/SG10201910742VA/en unknown
- 2016-05-26 EP EP19182836.7A patent/EP3569604B1/en active Active
- 2016-05-26 CN CN201680029912.9A patent/CN107667108B/zh active Active
- 2016-05-26 LT LT16728495T patent/LT3303348T/lt unknown
- 2016-05-26 PT PT167284959T patent/PT3303348T/pt unknown
- 2016-05-26 CN CN202010325911.7A patent/CN111362975B/zh active Active
- 2016-05-26 SM SM20190587T patent/SMT201900587T1/it unknown
- 2016-05-26 EA EA201792619A patent/EA032953B1/ru unknown
- 2016-05-26 ES ES19182836T patent/ES2924698T3/es active Active
- 2016-05-26 CA CA2983453A patent/CA2983453A1/en not_active Abandoned
- 2016-05-26 ME MEP-2019-289A patent/ME03610B/me unknown
- 2016-05-26 US US15/165,126 patent/US9725470B2/en active Active
- 2016-05-26 JP JP2017561259A patent/JP6692836B2/ja active Active
- 2016-05-26 MX MX2017015211A patent/MX378963B/es unknown
- 2016-05-26 ES ES16728495T patent/ES2753159T3/es active Active
- 2016-05-26 WO PCT/US2016/034243 patent/WO2016191524A1/en active Application Filing
- 2016-05-27 TW TW109132390A patent/TWI746178B/zh not_active IP Right Cessation
- 2016-05-27 TW TW105116751A patent/TWI704152B/zh not_active IP Right Cessation
-
2017
- 2017-06-23 US US15/631,220 patent/US10072026B2/en active Active
- 2017-10-27 ZA ZA2017/07326A patent/ZA201707326B/en unknown
- 2017-10-31 IL IL255358A patent/IL255358B/en active IP Right Grant
- 2017-11-09 PH PH12017502050A patent/PH12017502050A1/en unknown
- 2017-11-14 SA SA517390337A patent/SA517390337B1/ar unknown
- 2017-11-27 CL CL2017002994A patent/CL2017002994A1/es unknown
- 2017-11-29 CO CONC2017/0012267A patent/CO2017012267A2/es unknown
-
2018
- 2018-04-18 HK HK18105049.0A patent/HK1245771A1/zh not_active IP Right Cessation
- 2018-08-06 US US16/055,386 patent/US10494382B2/en active Active
-
2019
- 2019-10-11 US US16/599,434 patent/US10947254B2/en active Active
- 2019-11-06 CY CY20191101165T patent/CY1122279T1/el unknown
-
2020
- 2020-01-15 IL IL272057A patent/IL272057B/en active IP Right Grant
- 2020-03-19 JP JP2020049467A patent/JP6850922B2/ja active Active
- 2020-03-27 AU AU2020202181A patent/AU2020202181B2/en not_active Ceased
- 2020-08-12 IL IL276677A patent/IL276677B/en active IP Right Grant
- 2020-09-16 JP JP2020155460A patent/JP6942853B2/ja active Active
-
2021
- 2021-02-10 US US17/248,832 patent/US11780852B2/en active Active
- 2021-03-22 JP JP2021047526A patent/JP2021098757A/ja not_active Withdrawn
-
2023
- 2023-09-05 US US18/242,434 patent/US20240132520A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378963B (es) | Compuestos de naftiridina como inhibidores de quinasa jak. | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| ZA201802496B (en) | Jak kinase inhibitor compounds for treatment of respiratory disease | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| MX375674B (es) | Compuestos de carboxamida inhibidores de la actividad de cinasa rip2. | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| MX2016010571A (es) | Pirazolil-ureas como inhibidores de quinasas. | |
| MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
| EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
| PH12015502248B1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12015502746A1 (en) | Prodrug derivatives of substituted triazolopyridines | |
| EA202192822A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы |